| Autor: |
Martínez-López, Yoscelina Estrella, Neri-Rosario, Daniel, Esquivel-Hernández, Diego Armando, Padron-Manrique, Cristian, Vázquez-Jiménez, Aarón, Sánchez-Castañeda, Jean Paul, Girón-Villalobos, David, Mendoza-Ortíz, Cristian, Reyes-Escogido, María de Lourdes, Evia-Viscarra, Maria Lola, Aguilar-Garcia, Alberto, Resendis-Antonio, Osbaldo, Guardado-Mendoza, Rodolfo |
| Předmět: |
|
| Zdroj: |
Scientific Reports; 9/10/2024, Vol. 14 Issue 1, p1-16, 16p |
| Abstrakt: |
Lifestyle modifications, metformin, and linagliptin reduce the incidence of type 2 diabetes (T2D) in people with prediabetes. The gut microbiota (GM) may enhance such interventions' efficacy. We determined the effect of linagliptin/metformin (LM) vs metformin (M) on GM composition and its relationship to insulin sensitivity (IS) and pancreatic β-cell function (Pβf) in patients with prediabetes. A cross-sectional study was conducted at different times: basal, six, and twelve months in 167 Mexican adults with prediabetes. These treatments increased the abundance of GM SCFA-producing bacteria M (Fusicatenibacter and Blautia) and LM (Roseburia, Bifidobacterium, and [Eubacterium] hallii group). We performed a mediation analysis with structural equation models (SEM). In conclusion, M and LM therapies improve insulin sensitivity and Pβf in prediabetics. GM is partially associated with these improvements since the SEM models suggest a weak association between specific bacterial genera and improvements in IS and Pβf. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
